Continuous Administration of Subcutaneous Levodopa/Carbidopa (ND0612) Demonstrated Comparable Levodopa Pharmacokinetics to Levodopa/Carbidopa Intestinal Gel (LCIG)

被引：0
|
作者：
Adar, Liat [1 ]
Minei, Tamar Rachmilewitz [1 ]
Cohen, Yael [1 ]
Oren, Sheila [1 ]
机构：
[1] NeuroDerm Ltd, Rehovot, Israel
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S4.003
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Twenty four hour continuous levodopa-carbidopa intestinal gel (LCIG) reduces freezing of gait
    Chang, F. C.
    Wolfe, N.
    Tsui, D.
    Griffith, J. M.
    Mahant, N.
    Fung, V. S.
    MOVEMENT DISORDERS, 2014, 29 : S376 - S376
  • [22] Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
    Loens, Sebastian
    Chorbadzhieva, Elena
    Kleimann, Alexandra
    Dressler, Dirk
    Schrader, Christoph
    BRAIN AND BEHAVIOR, 2017, 7 (05):
  • [23] Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations
    Balestrino, R.
    Martone, T.
    Toffoli, M.
    Montanaro, E.
    Fabbri, M.
    Artusi, C. A.
    Romagnolo, A.
    Zibetti, M.
    Rizzone, M.
    Goldwurm, S.
    Lopiano, L.
    Schapira, A. H. V.
    NEUROLOGICAL SCIENCES, 2024, 45 (04) : 1489 - 1497
  • [24] THE EFFECT OF AN INCREASED RATIO OF CARBIDOPA TO LEVODOPA ON THE PHARMACOKINETICS OF LEVODOPA
    KAAKKOLA, S
    MANNISTO, PT
    NISSINEN, E
    VUORELA, A
    MANTYLA, R
    ACTA NEUROLOGICA SCANDINAVICA, 1985, 72 (04): : 385 - 391
  • [25] Pharmacokinetic-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
    Birnberg, T.
    Adar, L.
    Poewe, W.
    Bjornsson, M.
    Karlsson, M.
    MOVEMENT DISORDERS, 2021, 36 : S162 - S162
  • [26] CLINICAL STUDIES WITH LEVODOPA/CARBIDOPA INTESTINAL GEL
    Klivenyi Peter
    Vecsei Laszlo
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2014, 67 (1-2): : 5 - 8
  • [27] Long-Term Safety of Continuous Levodopa/Carbidopa Infusion with ND0612: Results from the Ongoing BeyoND Study
    Isaacson, S.
    Stocchi, F.
    Adar, L.
    Case, R.
    Sasson, N.
    Salin, L.
    Yardeni, T.
    Poewe, W.
    MOVEMENT DISORDERS, 2022, 37 : S10 - S10
  • [28] Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Signs of Parkinson's disease (PD) and Experiences of Daily Living
    Rascol, O.
    Isaacson, S.
    LeWitt, P.
    Poewe, W.
    Ferreira, J.
    Lopes, N.
    Sopromadze, S.
    Pereira, J.
    Olanow, C.
    MOVEMENT DISORDERS, 2024, 39 : S313 - S313
  • [29] Dietary Protein Redistribution Influences the Efficacy of levodopa/carbidopa Intestinal Gel (LCIG) Infusion
    Ben Mordechai, Y.
    Israeli-Korn, S.
    Cohen, O.
    Hassin-Baer, S.
    MOVEMENT DISORDERS, 2023, 38 : S853 - S853
  • [30] Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations
    R. Balestrino
    T. Martone
    M. Toffoli
    E. Montanaro
    M. Fabbri
    C. A. Artusi
    A. Romagnolo
    M. Zibetti
    M. Rizzone
    S. Goldwurm
    L. Lopiano
    A. H. V. Schapira
    Neurological Sciences, 2024, 45 : 1489 - 1497
12345